Evidence map›Paper›PMID 18439618›Full record

ArticleJournal of immunological methods2008

Rapid identification of MHC class I-restricted antigens relevant to autoimmune diabetes using retrogenic T cells.

Rodolfo José Chaparro, Amanda R Burton, David V Serreze, Dario A A Vignali, Teresa P DiLorenzo

Abstract read
In one paragraph

Article in Journal of immunological methods, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Opening opportunities for KCommunications biology · 2022
    Article
  2. Article
  3. Review
  4. Article
  5. Targeting the pancreatic β-cell to treat diabetes.Nature reviews. Drug discovery · 2014
    Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Rodolfo José ChaparroDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Amanda R Burton
David V Serreze
Dario A A Vignali
Teresa P DiLorenzo

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI SUZANNE J. BAKER · 1985 to 2026
$166.9M
WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI ALYSON B MOADEL · 1985 to 2026
$111.2M
Stable Isotope and Metabolomics CoreP60DK020541 · NIDDK · YESHIVA UNIVERSITY · PI PESSIN, JEFFREY E. · 1986 to 2014
$29.8M
Translational Research CoreP30DK020541 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI STREAMSON C CHUA · 2015 to 2026
$27.7M
Viral Immunoregulatory Genes in Beta Cells to Treat DiabetesP01DK052956 · NIDDK · YESHIVA UNIVERSITY · PI DILORENZO, TERESA P · 1998 to 2007
$8.5M
Diabetogenic Role of MHC Class I Alleles in NOD MiceR01DK046266 · NIDDK · JACKSON LABORATORY · PI SERREZE, DAVID V · 2000 to 2018
$7.2M
Molecular NeuropathologyT32NS007098 · NINDS · YESHIVA UNIVERSITY · PI SANTAMBROGIO, LAURA · 1985 to 2015
$5.0M
Antigens Recognized by CD8+ T Cells in Type 1 DiabetesR01DK064315 · NIDDK · YESHIVA UNIVERSITY · PI DILORENZO, TERESA P · 2003 to 2015
$3.8M
ANTIGEN PRESENTING CELL DEFECTS IN AUTOIMMUNE DIABETESR01DK051090 · NIDDK · JACKSON LABORATORY · PI SERREZE, DAVID V · 1996 to 2009
$3.0M
DIABETOGENIC ROLE OF H-2G7 CLASS I ALLELES IN NOD MICER29DK046266 · NIDDK · JACKSON LABORATORY · PI SERREZE, DAVID V. · 1993 to 1998
–
NCI NIH HHS CA 13330NCI NIH HHS CA 21765NCI NIH HHS P30 CA013330NCI NIH HHS P30 CA021765NIDDK NIH HHS DK 20541NIDDK NIH HHS DK 46266NIDDK NIH HHS DK 51090NIDDK NIH HHS DK 52956NIDDK NIH HHS DK 64315NIDDK NIH HHS P01 DK052956NIDDK NIH HHS P30 DK020541NIDDK NIH HHS P60 DK020541NIDDK NIH HHS R01 DK046266NIDDK NIH HHS R01 DK051090NIDDK NIH HHS R01 DK064315NIDDK NIH HHS R29 DK046266NINDS NIH HHS NS 07098NINDS NIH HHS T32 NS007098
6 · The paper itself

Abstract

The method described herein provides a novel strategy for the rapid identification of CD8(+) T cell epitopes relevant to type 1 diabetes in the context of the nonobese diabetic (NOD) mouse model of disease. Obtaining the large number of antigen-sensitive monospecific T cells required for conventional antigen discovery methods has historically been problematic due to (1) difficulties in culturing autoreactive CD8(+) T cells from NOD mice and (2) the large time and resource investments required for the generation of transgenic NOD mice. We circumvented these problems by exploiting the rapid generation time of retrogenic (Rg) mice, relative to transgenic mice, as a novel source of sensitive monospecific CD8(+) T cells, using the diabetogenic AI4 T cell receptor on NOD.SCID and NOD.Rag1(-/-) backgrounds as a model. Rg AI4 T cells are diabetogenic in vivo, demonstrating for the first time that Rg mice are a means for assessing the pathogenic potential of CD8(+) T cell receptor specificities. In order to obtain a sufficient number of Rg CD8(+) T cells for antigen screens, we optimized a method for their in vitro culture that resulted in a approximately 500 fold expansion. We demonstrate the high sensitivity and specificity of expanded Rg AI4 T cells in the contexts of (1) specific peptide challenge, (2) islet cytotoxicity, and (3) their ability to resolve previously defined mimotope candidates from a positional scanning peptide library. Our method is the first to combine the speed of Rg technology with an optimized in vitro Rg T cell expansion protocol to enable the rapid discovery of T cell antigens.

Indexed as

Immunologic TechniquesAnimalsCD8-Positive T-LymphocytesCell Culture TechniquesCell ProliferationCells, CulturedCytotoxicity, ImmunologicDiabetes Mellitus, Type 1Disease Models, AnimalFlow CytometryHematopoietic Stem Cell TransplantationHistocompatibility Antigens Class IHomeodomain ProteinsHumansIslets of LangerhansMiceHistocompatibility Antigens Class IHomeodomain ProteinsPeptide LibraryRAG-1 proteinReceptors, Antigen, T-Cell, alpha-beta

Identifiers

PMID18439618
PMCPMC2430474

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.